Format

Send to

Choose Destination
Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003.

Current clinical trials testing combinations of immunotherapy and radiation.

Author information

1
Earle A. Chiles Research Institute, Portland, OR. Electronic address: marka.crittenden@providence.org.
2
Department of Medicine, Division of Oncology, Stanford University, Stanford, CA.
3
National Cancer Institute, Bethesda, MD.
4
Department of Radiation Oncology Branch, National Cancer Institute, Bethesda, MD.
5
Department of Radiation Oncology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA.
6
Department of Pathology, New York University School of Medicine, New York, NY.
7
Department of Radiation Oncology, New York University, New York, NY.

Abstract

Preclinical evidence of successful combinations of ionizing radiation with immunotherapy has inspired testing the translation of these results to the clinic. Interestingly, the preclinical work has consistently predicted the responses encountered in clinical trials. The first example came from a proof-of-principle trial started in 2001 that tested the concept that growth factors acting on antigen-presenting cells improve presentation of tumor antigens released by radiation and induce an abscopal effect. Granulocyte-macrophage colony-stimulating factor was administered during radiotherapy to a metastatic site in patients with metastatic solid tumors to translate evidence obtained in a murine model of syngeneic mammary carcinoma treated with cytokine FLT-3L and radiation. Subsequent clinical availability of vaccines and immune checkpoint inhibitors has triggered a wave of enthusiasm for testing them in combination with radiotherapy. Examples of ongoing clinical trials are described in this report. Importantly, most of these trials include careful immune monitoring of the patients enrolled and will generate important data about the proimmunogenic effects of radiation in combination with a variety of immune modulators, in different disease settings. Results of these studies are building a platform of evidence for radiotherapy as an adjuvant to immunotherapy and encourage the growth of this novel field of radiation oncology.

PMID:
25481267
PMCID:
PMC4640687
DOI:
10.1016/j.semradonc.2014.07.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center